High-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferation

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Goel, Shakti A ^a   Guo, Lian Wang ^a   Wang, Bowen ^a   Guo, Song ^b   Roenneburg, Drew ^a   Ananiev, Gene E ^b   Hoffmann, F Michael ^b   Kent, K Craig ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; CERIVASTATIN; DACTINOMYCIN; HOMOHARRINGTONINE; IDARUBICIN; RESVERATROL; SDM 25N; TRIPTOLIDE; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; AUTOMATION; CAROTID ARTERY INJURY; CAROTID ARTERY OBSTRUCTION; CELL ASSAY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; EPITHELIZATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; SMOOTH MUSCLE FIBER; TISSUE REGENERATION; VASCULAR ENDOTHELIUM; ANIMAL; CELL CULTURE; DRUG EFFECTS; HYPERPLASIA; INTIMA; PROCEDURES; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYPERPLASIA; IDARUBICIN; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, SPRAGUE-DAWLEY; TUNICA INTIMA;

EID: 84897799216     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089349     Document Type: Article

References (42)

1. Mills B, Robb T, Larson DF (2012) Intimal hyperplasia: slow but deadly. Perfusion 27: 520-528.
2. Suwanabol PA, Kent KC, Liu B (2011) TGF-beta and restenosis revisited: a Smad link. J Surg Res 167: 287-297.
3. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al. (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA: the journal of the American Medical Association 293: 2126-2130.
4. Curcio A, Torella D, Coppola C, Mongiardo A, Cireddu M, et al. (2002) Coated stents: a novel approach to prevent in-stent restenosis. Italian heart journal: official journal of the Italian Federation of Cardiology 3 Suppl 4: 16S-19S.
5. Simon DI (2012) Inflammation and vascular injury. Circulation journal: official journal of the Japanese Circulation Society 76: 1811-1818.
6. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, et al. (2005) Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46: 231-236. (Pubitemid 40966848)
7. Mills B, Robb T, Larson DF (2012) Intimal Hyperplasia: slow but deadly. Perfusion.
8. Curcio A, Torella D, Indolfi C (2011) Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circulation journal: official journal of the Japanese Circulation Society 75: 1287-1296.
9. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, et al. (2005) Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. The New England journal of medicine 353: 653-662. (Pubitemid 41175673)
10. Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, et al. (2010) Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 55: 2710-2716.
11. Inoue T, Croce K, Morooka T, Sakuma M, Node K, et al. (2011) Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovascular interventions 4: 1057-1066.
12. Giordano A, Romano S, Monaco M, Sorrentino A, Corcione N, et al. (2012) Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells. Am J Physiol Heart Circ Physiol 302: H135-142.
13. Sun L, Zhao R, Zhang L, Zhang T, Xin W, et al. (2012) Salvianolic acid A inhibits PDGF-BB induced vascular smooth muscle cell migration and proliferation while does not constrain endothelial cell proliferation and nitric oxide biosynthesis. Molecules 17: 3333-3347.
14. Vallieres K, Petitclerc E, Laroche G (2009) On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study. Vascular pharmacology 51: 50-56.
15. Hacker TA, Griffin MO, Guttormsen B, Stoker S, Wolff MR (2007) Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo. J Invasive Cardiol 19: 269-274. (Pubitemid 46828017)
16. Yoon JW, Cho BJ, Park HS, Kang SM, Choi SH, et al. (2012) Differential effects of trimetazidine on vascular smooth muscle cell and endothelial cell in response to carotid artery balloon injury in diabetic rats. International journal of cardiology.
17. Forte A, Grossi M, Turczynska KM, Svedberg K, Rinaldi B, et al. (2013) Local inhibition of ornithine decarboxylase reduces vascular stenosis in a murine model of carotid injury. International journal of cardiology 168: 3370-3380.
18. Liu X, Cheng Y, Yang J, Xu L, Zhang C (2012) Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol 52: 245-255.
19. Yao EH, Fukuda N, Ueno T, Matsuda H, Nagase H, et al. (2009) A pyrroleimidazole polyamide targeting transforming growth factor-beta1 inhibits restenosis and preserves endothelialization in the injured artery. Cardiovasc Res 81: 797-804.
20. Breen DM, Dolinsky VW, Zhang H, Ghanim H, Guo J, et al. (2012) Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Atherosclerosis 222: 375-381.
21. Nociari MM, Shalev A, Benias P, Russo C (1998) A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. Journal of immunological methods 213: 157-167. (Pubitemid 28332808)
22. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Journal of biomolecular screening 4: 67-73. (Pubitemid 29278954)
23. Kundi R, Hollenbeck ST, Yamanouchi D, Herman BC, Edlin R, et al. (2009) Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. Cardiovasc Res 84: 326-335.
24. Ji R, Cheng Y, Yue J, Yang J, Liu X, et al. (2007) MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 100: 1579-1588. (Pubitemid 46897261)
25. Kingston PA, Sinha S, Appleby CE, David A, Verakis T, et al. (2003) Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty. Circulation 108: 2819-2825. (Pubitemid 37498986)
26. Nugent HM, Rogers C, Edelman ER (1999) Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ Res 84: 384-391. (Pubitemid 29120003)
27. Tian W, Kuhlmann MT, Pelisek J, Scobioala S, Quang TH, et al. (2006) Paclitaxel delivered to adventitia attenuates neointima formation without compromising re-endothelialization after angioplasty in a porcine restenosis model. Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists 13: 616-629.
28. Brown MA, Zhang L, Levering VW, Wu JH, Satterwhite LL, et al. (2010) Human umbilical cord blood-derived endothelial cells reendothelialize vein grafts and prevent thrombosis. Arterioscler Thromb Vasc Biol 30: 2150-2155.
29. Antczak C, Shum D, Escobar S, Bassit B, Kim E, et al. (2007) High-throughput identification of inhibitors of human mitochondrial peptide deformylase. Journal of biomolecular screening 12: 521-535. (Pubitemid 46871829)
30. Sachsenmeier KF, Hay C, Brand E, Clarke L, Rosenthal K, et al. (2012) Development of a novel ectonucleotidase assay suitable for high-throughput screening. Journal of biomolecular screening 17: 993-998.
31. Wessely R, Schomig A, Kastrati A (2006) Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol 47: 708-714. (Pubitemid 43243089)
32. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, et al. (2006) Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. European heart journal 27: 166-170. (Pubitemid 43069032)
33. Torella D, Gasparri C, Ellison GM, Curcio A, Leone A, et al. (2009) Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85alphaPI3K. Am J Physiol Heart Circ Physiol 297: H2015-2025.
34. Song P, Wang S, He C, Liang B, Viollet B, et al. (2011) AMPKalpha2 deletion exacerbates neointima formation by upregulating Skp2 in vascular smooth muscle cells. Circ Res 109: 1230-1239.
35. Li FY, Lam KS, Tse HF, Chen C, Wang Y, et al. (2012) Endothelium- selective activation of AMP-activated protein kinase prevents diabetes mellitus-induced impairment in vascular function and reendothelialization via induction of heme oxygenase-1 in mice. Circulation 126: 1267-1277.
36. Ewald JA, Peters N, Desotelle JA, Hoffmann FM, Jarrard DF (2009) A high-throughput method to identify novel senescence-inducing compounds. Journal of biomolecular screening 14: 853-858.
37. Tomasini-Johansson BR, Johnson IA, Hoffmann FM, Mosher DF (2012) Quantitative microtiter fibronectin fibrillogenesis assay: use in high throughput screening for identification of inhibitor compounds. Matrix biology: journal of the International Society for Matrix Biology.
38. Mukadam S, Tay S, Tran D, Wang L, Delarosa EM, et al. (2012) Evaluation of time-dependent cytochrome p450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach. Drug metabolism letters 6: 43-53.
39. Volkova M, Russell R 3rd (2011) Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Current cardiology reviews 7: 214-220.
40. Gertz ZM, Wilensky RL (2011) Local drug delivery for treatment of coronary and peripheral artery disease. Cardiovascular therapeutics 29: e54-66.
41. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, et al. (2008) Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 118: 1358-1365.
42. Cremers B, Schmitmeier S, Clever YP, Gershony G, Speck U, et al. (2013) Inhibition of neo-intimal hyperplasia in porcine coronary arteries utilizing a novel paclitaxel-coated scoring balloon catheter. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions.